Articles tagged with Tuberculosis
A new TB prevention regimen for HIV-positive individuals has shown promising results, with 90.4% completing the three-month course compared to 50.5% of those on a six-month daily treatment. The study suggests that this shorter approach is as safe and effective as the standard treatment.
A randomized trial found that a shorter course of rifapentine-isoniazid therapy resulted in significantly higher treatment completion rates compared to a longer daily course. The findings suggest that this regimens can be more effective for preventing tuberculosis disease in individuals with HIV, particularly in high-transmission areas.
Researchers at Purdue University and Houston Methodist have developed a novel TB vaccine formulation that enhances T cell responses to combat tuberculosis. The new vaccine uses autophagy-mediated antigen presentation, showing promising results in improving immune response.
Scientists at Rockefeller University have discovered that essential gene targets in TB bacteria can be ranked by their degree of vulnerability to antibiotics. The study found that ideal targets are highly susceptible to inhibition, while invulnerable genes can withstand nearly total inhibition. This research provides new insights into ...
Researchers at the University of Maryland discovered a gene in tuberculosis that inhibits the inflammasome, a signaling system that helps defend against pathogens. The finding may lead to effective gene-based treatments or preventative therapies for tuberculosis.
Researchers created a 3D view of diseased lung tissue using microCT to reveal that TB granulomas are complex and branched, with unique connections to airways. This has significant implications for treatment, including the potential for aerosolized drug delivery to reduce treatment times.
The UNITE4TB partnership aims to develop new and highly active TB treatment regimens for drug-resistant and -sensitive TB. The 7-year project will utilize advanced clinical trials networks, adaptive trial designs, and machine learning techniques to accelerate the development of better treatment solutions.
The UNITE4TB partnership aims to develop new and highly active TB treatment regimens for drug-resistant and -sensitive TB. The consortium will accelerate the clinical evaluation of combinations of existing and novel drugs through advanced trial designs and AI-powered analysis.
Researchers have discovered a new approach to treating tuberculosis by boosting the body's immune system and targeting cell death pathways. The study found that using preclinical models, infected cells can be killed by drugs called IAP inhibitors, significantly reducing disease severity.
A study published at ECCMID 2021 found that individuals with depression and schizophrenia have a higher incidence of TB. The research suggests that mental health may play a causal role in increasing TB risk, particularly through its effect on the immune system.
Scientists from Hackensack Meridian Center for Discovery and Innovation have uncovered the mechanism of action of a novel anti-tuberculosis drug, triaza-coumarin, which is effective in inhibiting TB disease from within by boosting its on-target activity by two orders of magnitude.
The study of Mycobacterium tuberculosis's ESX-5 secretion system reveals a complex molecular machinery that enables the bacterium to infect human cells. The structure of this system provides potential drug targets and new insights into vaccine development.
A Phase 2 trial showed that combining doxycycline with TB treatment reduces lung cavity size and increases markers of recovery in pulmonary TB patients. This discovery has promise for preventing long-term complications and improving outcomes for those affected by the disease.
A comprehensive health-screening program in rural northern KwaZulu-Natal, South Africa, has identified a high burden of undiagnosed or poorly controlled non-communicable diseases. The study found that four out of five women over the age of 30 were living with chronic health conditions, highlighting the need for urgent interventions.
A new study validates the Xpert Ultra molecular test as a frontline tool in routine conditions, showing improved sensitivity over its predecessor. The test detects tuberculosis cases with lower bacterial burdens and can identify asymptomatic cases in early stages of the disease.
Researchers discovered a stem cell-mediated defense mechanism that reactivates dormant tuberculosis in mice infected with SARS-CoV-2, suggesting potential for new vaccines and avoiding global TB pandemic. This discovery may help develop novel therapeutic approaches against COVID-19 and target antiviral activities.
Researchers have identified seven genes responsible for excessive inflammation and damage to the lungs in tuberculosis. A new drug treatment, doxycycline, has shown promise in reducing lung damage and accelerating recovery in patients with pulmonary TB.
Researchers have found a new four-month antibiotic regimen using rifapentine to be effective in treating TB, reducing the treatment duration by two months. The study showed that patients with HIV also cleared their TB just as well as those without HIV.
A recent study on TB outbreak in an Irish prison highlights the need for increased testing and improved care. The study found that 50% of staff may have developed latent TB as a result of occupational exposure, posing a risk of progression to active TB.
A multinational study validated a four-month multi-drug therapy regimen as effective as the standard six-month treatment for active tuberculosis, reducing treatment time by a third. The new regimen, which includes rifapentine and moxifloxacin, was safe and well-tolerated.
Researchers developed a new basis for comparing tuberculosis treatments using an rRNA synthesis ratio, enabling more intelligent drug design and acceleration of treatments. This tool has crucial implications for combatting the global TB epidemic by providing a durable cure.
The new test detects a specific protein (CFP-10) in children's blood samples with high sensitivity and accuracy, identifying TB cases with 100% accuracy. It can detect TB up to 60 weeks before diagnosis, offering early detection and potentially saving lives.
Scientists at the University of Surrey detail how they measure metabolite fluxes in Mycobacterium tuberculosis, crucial for understanding its survival and developing effective treatments. This breakthrough could accelerate progress towards eliminating tuberculosis globally.
A groundbreaking study has identified IL-17 cytokine as the primary culprit behind excessive lung inflammation in TB patients. By targeting this pathway, doctors may be able to reduce disease harm and speed up patient recovery.
Researchers developed a genetic material-based catalogue to predict antibiotic resistance in MDR-TB, enabling accelerated treatment development. The study found that 99% of predicted drug combinations were effective in traditional microbiological testing.
New research reveals fundamental differences in how baby and adult immune cells respond to TB, with a greater ability of adult cells to shift their energy profile after infection. The study highlights the importance of understanding how the immune system uses energy to develop better treatments for vulnerable populations.
Researchers at the University of Alabama at Birmingham have discovered a novel protein transport system in Mycobacterium tuberculosis, allowing the release of its toxin, tuberculosis necrotizing toxin (TNT), into human macrophages. The study reveals that two small Esx proteins form pores in membranes to facilitate TNT secretion.
Researchers identified Mycobacterium tuberculosis' use of rubredoxin B to survive in iron-deficient conditions, helping the bacterium evade the immune system. The study provides new insights into the development of drug resistance and potential targets for therapeutic agents.
A new report by Harvard Medical School researchers found that TB diagnoses in the US are often delayed, leading to a higher likelihood of infection transmission and disease progression. The study suggests that increased clinician awareness and education can help minimize these delays.
The TB burden in Europe is decreasing, with a 19% overall decline from 2015-2019. However, drug resistance remains a major concern, and the COVID-19 pandemic may stall or cause setbacks in the fight against TB. Treatment outcomes are suboptimal, with only 77% of patients successfully completing treatment in 2019.
Researchers found that adding an iron binder to Bedaquiline treatment boosts its ability to combat TB bacteria. The study suggests a promising approach to improving patient outcomes and developing new treatments.
Researchers at Radboud University Medical Center have found that a higher dose of the anti-tuberculosis drug rifampicin is safe and effective. This could lead to a shorter treatment duration and less resistance, with potential benefits for global tuberculosis treatment.
Researchers analyzed ancient human DNA to understand the impact of tuberculosis on European populations. The study found that a specific variant of the TYK2 gene was associated with an increased risk of becoming ill after infection with Mycobacterium tuberculosis.
Researchers analyzed 70,000 ancient skeletons to find declining rates of transmission for these chronic infectious diseases. The analysis suggests that pathogens may evolve to cause less harm to humans over time, leading to reduced transmission.
A MUSC researcher has been awarded a $9.9 million contract to test TB treatment interventions in areas with severe disease prevalence. The goal is to shorten treatment duration and improve patient adherence, particularly for individuals with latent TB infection.
Researchers found a genetic mechanism in Mycobacterium tuberculosis that allows the bacterium to respond to stress rapidly and in manner that is 'history-dependent.' The study suggests this mechanism may be key to understanding tuberculosis latency, a global health problem affecting 2-3 billion people.
Researchers have isolated monoclonal antibodies that effectively target and inhibit the growth of tuberculosis germs in laboratory mice. These biological antibiotics show promise as an alternative to traditional chemical antibiotics, offering a safer and more stable treatment option.
A new biomarker has been identified that can determine individual treatment duration for tuberculosis patients, reducing the need for prolonged therapy. The biomarker is based on an RNA signature from 22 genes and was developed using patient cohorts from Germany and Romania.
Research found fidaxomicin is more effective than existing TB medication at preventing growth of M. tuberculosis, including resistant strains. Fidaxomicin's in vitro activity was compared to rifampicin and showed promise as a potential new treatment for TB.
Researchers propose a new TB drug targeting the FtsZ protein, inhibiting cell division and suppressing growth, with potential for long-term effectiveness. The compound has been identified through high-precision molecular simulations, offering a novel solution to the problem of drug resistance in TB.
Researchers at the University of Sydney have developed a novel method to rapidly synthesize safe vaccines using protein-based immunization. The approach demonstrated strong immune response in mice against tuberculosis and has potential applications for respiratory diseases, including COVID-19.
Researchers developed a new imaging method to track antibiotic distribution in infected tissues, revealing that some antibiotics only partially penetrate infected cells. This discovery could lead to more targeted treatments and reduced risk of antibiotic resistance.
A new lung-on-chip model has provided insight into the body's response to early tuberculosis infection. The study revealed that alveolar epithelial cells play a crucial role in controlling bacterial growth by producing surfactant, which reduces surface tension and prevents uncontrolled bacterial growth.
Researchers at San Diego State University have uncovered a crucial clue to the mystery of TB's rapid resistance to antibiotics. They found that the pathogen uses an epigenetic domain to diversify and create multiple subpopulations with varying phenotypes, leading to drug resistance.
Research highlights the need for tuberculosis (TB) screening and ongoing clinical care for people on methotrexate living in areas with high TB prevalence. Methotrexate users taking corticosteroids or immunosuppressants are at increased risk of TB infection.
A study found that prenatal and early-life exposure to the Great Chinese Famine significantly increases the risk of pulmonary tuberculosis (PTB) in adulthood across two generations. Over 12,000 active PTB cases were attributed to famine exposure between 2005 and 2018 in Sichuan Province.
Researchers at MIT developed a machine-learning algorithm that can predict the effectiveness of drug compounds against tuberculosis and other diseases. The algorithm, which incorporates uncertainty values to account for data variability, identified promising compounds targeting a critical protein required by the bacteria.
A new TB vaccine developed by Dartmouth's Geisel School of Medicine has shown promising results in a Phase 2 trial, inducing immune responses against the disease. The vaccine was safe and well-tolerated, with minimal local reactions, and may prevent TB disease by inducing a favorable immune response.
Researchers at NTNU have filmed the process of tuberculosis infection in a cell, revealing how the bacterium evades the body's immune system. The study shows how TB bacteria hide inside macrophages and trigger an explosive immune response to spread further.
A new study from the Max Planck Institute of Geoanthropology has reconstructed a tuberculosis genome from the calcified lungs of a 17th-century bishop, supporting the idea that TB emerged within the last 6,000 years. The discovery sheds light on the origins of TB and challenges the prevailing assumption about its global distribution.
A new international study has shown that a newly developed treatment regimen for multidrug-resistant tuberculosis (MDR-TB) is highly effective, with an 85% success rate among patients with serious comorbidities. The regimens, bedaquiline and delamanid, offer a promising alternative to the historical standard of care, which has approxim...
A new vaccine candidate BCG::RD1 has shown highly protective effects against tuberculosis in older mice with type 2 diabetes. The vaccine acts on multiple immune cell subsets to mount a robust response against TB-causing bacteria.
The study found that implementing antiretroviral therapy (ART) for HIV and newer tuberculosis medications decreases the risk of death for adults with drug-resistant TB. Access to these life-saving medications varies widely globally.
A recent study published in Cell Reports Medicine found that the BCG vaccine is safe and does not increase the risk of COVID-19 symptoms. The research also suggests a cautiously positive picture, with lower numbers of sick people and extreme fatigue among vaccinated individuals during the pandemic.
Researchers at Johns Hopkins Medicine found that a next-generation cholesterol-lowering drug can lower blood cholesterol to safer levels faster when added to traditional therapies. The study showed significant reductions in LDL cholesterol during hospitalization and within a month following a heart attack, suggesting the drug is safe a...
Compounds tested for their potential as antibiotics have demonstrated promising activity against tuberculosis (TB), a deadly infectious disease caused by Mycobacterium tuberculosis. The study found that the compounds exploit well-known targets for drugs, including the bacterial enzyme DNA gyrase.
Researchers at Durham University have found a new toxin, called MenT, produced by the TB bacterium Mycobacterium tuberculosis. This toxin inhibits the use of amino acids needed for protein production, causing the bacteria to die. The discovery opens up new avenues for treating tuberculosis and other infections.
A new technology dubbed MorphEUS enables rapid screening of drug candidates against Mycobcterium tuberculosis (M. tb), the bacterium that causes TB. It uses high throughput imaging and machine learning to uncover patterns in how antibacterials kill, improving the efficiency and effectiveness of treatment development.
Scientists at Trinity College Dublin discovered a way to manipulate human immune responses to Mycobacterium tuberculosis, tipping the balance in favor of patients. The study used an epigenetic inhibitor to release pro-inflammatory signals that aid in clearing the infection, promoting future vaccine strategies.
A novel mouse model shows that contained and persistent yet non-pathogenic Mtb infection reduces tuberculosis disease burden after re-exposure. The study highlights the importance of innate immune responses in protecting against the disease.